Gilead’s Kite Receives FDA Nod to Add Overall Survival Data to Yescarta for Large B-Cell Lymphoma

Gilead Sciences Inc. (NASDAQ: GILD) subsidiary Kite has received approval from the U.S. Food and Drug Administration (FDA) to update the label of Yescarta (axicabtagene ciloleucel) to include overall survival (OS) data for its use as a second-line treatment for relapsed or refractory large B-cell lymphoma (r/r LBCL). This new information aims to bolster healthcare provider confidence, demonstrating that during a Phase III study, the CAR T-cell therapy improved OS by 38% and reduced the risk of death by 27.4% compared to the standard of care, which involves a multi-step process including stem-cell transplant.- Flcube.com